Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• The human mutT homolog-1 (MTH1) protein hydrolyzes oxidized nucleotides, preventing their incorporation into DNA during replication.
• MTH1's role in cancer cell survival under oxidative stress has been proposed as a therapeutic target.
• Recent evidence challenges the direct anti-cancer effects of MTH1 inhibitors, suggesting off-target mechanisms.

Purpose of the Study:

• To detail the identification process for novel purine-based MTH1 inhibitors.
• To investigate the structure-activity relationships of these inhibitors.
• To provide insights into the binding modes of MTH1 inhibitors through molecular docking.

Main Methods:

• Identification and synthesis of purine-based compounds targeting MTH1.
• Determination of inhibitor potency, including submicromolar range compounds.
• Structure-activity relationship analysis and molecular docking for binding mode prediction.

Main Results:

• Several new purine-based MTH1 inhibitors with submicromolar potency were identified.
• Detailed structure-activity relationships were established for the identified compounds.
• Molecular docking provided predictive insights into the binding modes of these inhibitors.

Conclusions:

• The study successfully identified novel purine-based MTH1 inhibitors with significant potency.
• Structure-activity relationship and molecular docking analyses offer a foundation for developing more effective MTH1 inhibitors.
• These findings contribute to understanding MTH1 inhibition strategies in cancer research.